LEO Pharma buys Replay to expand rare skin gene therapy push: full analysis
LEO Pharma is making a bigger bet on rare dermatology, announcing on April 30, 2026, that it has signed a definitive agreement to acquire Replay and its gene therapy platform for rare genetic skin diseases. The acquisition brings Replay’s high-payload HSV delivery technology into LEO’s pipeline, with the lead asset focused on dystrophic epidermolysis bullosa, a severe inherited blistering disorder with substantial unmet need. (leo-pharma.com)
The move builds on LEO’s broader push into rare skin disease. Reuters reported that the company has already expanded its footprint through its partnership around Spevigo and a 2025 strategic partnership with DEBRA Research focused on epidermolysis bullosa. In that February 2025 announcement, LEO and DEBRA Research said they would work together to identify and advance therapeutic opportunities for rare skin diseases, signaling that EB had already become an area of strategic interest for the company before the Replay deal emerged. (wdez.com)
LEO said Replay’s platform uses engineered HSV vectors with natural tropism for skin cells and enough payload capacity to deliver large genes, a meaningful feature in diseases driven by mutations that are difficult to address with smaller vector systems. The therapy is formulated as a topical gel applied directly to the skin, and the lead DEB candidate remains in preclinical studies. In its Q1 2026 interim report, LEO said the acquisition is meant to strengthen innovation in rare genetic skin diseases and that the incoming Replay team adds in-house HSV design and manufacturing expertise. (leo-pharma.com)
Financially, Reuters reported the agreement includes $50 million upfront, with additional milestone payments and tiered single-digit royalties. BioWorld described Replay as a seed-stage company, underscoring that LEO is buying platform potential and technical capability as much as a near-term product. Reuters also noted that the deal comes as LEO prepares for a possible stock-market listing, suggesting the company is trying to show investors where future growth could come from in a competitive dermatology market. That last point is an inference based on Reuters’ reporting about LEO’s IPO preparations and deal strategy. (wdez.com)
The timing also fits a broader shift in EB treatment. The FDA approved Vyjuvek, a topical HSV-1 gene therapy for wounds in patients with dystrophic epidermolysis bullosa, in August 2023, and approved Zevaskyn, an autologous cell sheet-based gene therapy for wounds in recessive dystrophic epidermolysis bullosa, in April 2025. Scientific American described these advances as the start of a new era in precision treatment for rare genetic skin disease, though experts also cautioned that access, cost, and incomplete systemic benefit remain challenges. (fda.gov)
Industry and expert commentary around the field has been cautiously optimistic. In LEO’s release, CEO Christophe Bourdon said the acquisition positions the company at the forefront of next-generation gene therapy in dermatology, while Replay CEO Lachlan MacKinnon said HSV’s skin tropism and redosing potential make it well suited to rare dermatologic disease. Separately, dermatologist Emily Gorell told Scientific American that current gene therapies for EB are important advances, but not cures, because they primarily address skin manifestations rather than internal tissue involvement. (leo-pharma.com)
Why it matters: For veterinary professionals, the immediate commercial impact is limited because this is a human dermatology transaction, not an animal health launch. Still, it’s relevant as a signal about where skin-disease innovation is heading: toward topical, locally delivered, genetically targeted therapies that may eventually reshape how the field thinks about chronic wounds, inherited barrier disorders, and precision dermatology. It also highlights how platform technologies, manufacturing know-how, and rare-disease expertise are becoming strategic assets, not just individual drug candidates. (leo-pharma.com)
What to watch: The next milestones are likely to be preclinical updates on Replay’s DEB program, any timeline for first-in-human development, and signs that LEO intends to broaden the platform into other rare genetic skin diseases. Just as important will be whether the company can translate scientific promise into a practical treatment path in a field where recent approvals have validated the concept, but reimbursement, manufacturing, and access still shape real-world uptake. (wdez.com)